Supriya Lifescience Ltd. has announced a board meeting scheduled for May 27, 2026. The board will convene to review and approve the company’s audited financial results for the quarter and the full financial year ended March 31, 2026. Furthermore, the meeting will address a potential recommendation for a dividend payout to equity shareholders for the completed fiscal year.
Reviewing Annual Performance
The company’s Board of Directors is set to meet on May 27, 2026, to evaluate the financial health and operational outcomes of the firm for the fourth quarter and the full fiscal year concluding on March 31, 2026. This review marks a critical milestone for stakeholders as the company prepares to disclose its audited performance for the 2025-26 period.
Dividend Consideration
Beyond the financial review, the board will deliberate on the recommendation of a dividend on the company’s equity shares for the financial year ended March 31, 2026. Any proposed dividend will be subject to approval and further announcements following the board meeting.
Trading Window Update
In accordance with corporate governance policies regarding the prevention of insider trading, the company has implemented a closure of its ‘Trading Window.’ This restriction for designated persons and their immediate relatives has been in effect since April 1, 2026, and will remain closed until 48 hours following the official declaration of the audited financial results on May 27, 2026.
Source: BSE
